Rich Adcock, ImmunityBio CEO
April 23, 2024 07:26 AM EDTUpdated 09:29 AM
FDA+

FDA ap­proves Im­mu­ni­ty­Bio's blad­der can­cer ther­a­py com­bo

Katherine Lewin

News Reporter

Im­mu­ni­ty­Bio scored an FDA ap­proval for its once-re­ject­ed drug com­bo for blad­der can­cer, the biotech an­nounced Mon­day, send­ing its stock up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times